loading...| Preferred Name |
Golimumab |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C87766 |
| CAS_Registry |
476181-74-5 |
| code |
C87766 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
A human monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-a) with immunosuppressive activity. Golimumab binds to TNF-a, thereby preventing TNF-a-mediated immune responses. TNF-a production is dysregulated in various auto-immune diseases and in cancer. |
| Display_Name |
Golimumab |
| FDA_UNII_Code |
91X1KLU43E |
| FULL_SYN |
Golimumab Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Alpha) (Human Monoclonal CNTO 148 Gamma-1-Chain), Disulfide with Human Monoclonal CNTO 148 Kappa-Chain, Dimer CNTO 148 GOLIMUMAB |
| label |
Golimumab |
| NCI_Drug_Dictionary_ID |
791699 |
| PDQ_Closed_Trial_Search_ID |
791699 |
| PDQ_Open_Trial_Search_ID |
791699 |
| Preferred_Name |
Golimumab |
| prefixIRI |
Thesaurus:C87766 |
| prefLabel |
Golimumab |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C2353893 |
| subClassOf |